Literature DB >> 11466563

Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites.

G Mantovani1, A Macciò, C Madeddu, L Mura, E Massa, M C Mudu, C Mulas, M R Lusso, G Gramignano, M B Piras.   

Abstract

Leptin is a recently identified hormone produced by the adipocyte ob gene which acts as a negative feedback signal critical to the normal control of food intake and body weight. A number of proinflammatory cytokines, such as interleukin 6, tumor necrosis factor alpha, and interferon gamma, have been proposed as mediators of cancer cachexia; these data suggest that abnormalities in leptin production/release or in its feedback mechanism play a role in cancer patients. We therefore studied the relationship between serum leptin and serum cytokines interleukin 6 and tumor necrosis factor alpha levels in advanced-stage cancer patients. Twenty-nine advanced stage cancer patients (all but one stage IV) with tumors at various sites were included in the study. A direct correlation between body mass index and serum leptin levels was found both in cancer patients and in healthy individuals. The serum levels of interleukin 6 were significantly higher in cancer patients than in healthy individuals. In cancer patients an inverse correlation was found between serum levels of leptin and proinflammatory cytokines. There was an inverse correlation between the Eastern Cooperative Oncology Group performance status scale and serum levels of leptin. Regarding survival, patients with very high serum levels of proinflammatory cytokines and very low levels of leptin had very short survival. Although obtained in a cancer patient population not overtly cachectic, our results provide further evidence that a simple dysregulation of leptin production and/or release cannot be involved in cancer-associated pathophysiological changes leading to cachexia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466563     DOI: 10.1007/s001090100234

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  20 in total

1.  Anthropometric measurements in non-small-cell lung cancer.

Authors:  Giovanni Mantovani
Journal:  Support Care Cancer       Date:  2002-07       Impact factor: 3.603

2.  Does megestrol acetate down-regulate interleukin-6 in patients?

Authors:  Giovanni Mantovani
Journal:  Support Care Cancer       Date:  2002-04-04       Impact factor: 3.603

3.  Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications.

Authors:  Antonio Macciò; Clelia Madeddu; Giulia Gramignano; Carlo Mulas; Carlo Floris; Daniela Massa; Giorgio Astara; Paola Chessa; Giovanni Mantovani
Journal:  J Mol Med (Berl)       Date:  2010-03-26       Impact factor: 4.599

Review 4.  Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.

Authors:  Kimberlee Burckart; Sorin Beca; Randall J Urban; Melinda Sheffield-Moore
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-07       Impact factor: 4.294

5.  Adipokines and systemic inflammation in weight-losing lung cancer patients.

Authors:  Sule T Gulen; Fisun Karadag; Aslihan B Karul; Naciye Kilicarslan; Emel Ceylan; Nilgun K Kuman; Orhan Cildag
Journal:  Lung       Date:  2012-01-14       Impact factor: 2.584

Review 6.  The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  J Mol Med (Berl)       Date:  2013-09-21       Impact factor: 4.599

7.  Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.

Authors:  Faruk Tas; Derya Duranyildiz; Andac Argon; Hilal Oğuz; Hakan Camlica; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

8.  Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. By Declan Walsh et al. Supportive Care in Cancer (2003) 11:60-62.

Authors:  Giovanni Mantovani
Journal:  Support Care Cancer       Date:  2003-05-13       Impact factor: 3.603

9.  Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.

Authors:  Giovanni Mantovani; Antonio Macciò; Clelia Madeddu; Loredana Mura; Giulia Gramignano; Maria Rita Lusso; Elena Massa; Miria Mocci; Roberto Serpe
Journal:  J Mol Med (Berl)       Date:  2003-08-19       Impact factor: 4.599

10.  l-carnitine and cancer cachexia: Clinical and experimental aspects.

Authors:  Renata Silvério; Alessandro Laviano; Filippo Rossi Fanelli; Marília Seelaender
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-01-26       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.